The newly established role is an exciting and essential development in the continuing growth of the company. In his role, Matt will oversee an increasingly diverse range of new projects along with delivering consistency of service and expert guidance to the company’s clients across qualitative and quantitative methodologies.

Most recently working in a freelance capacity, Matt is a skilled and adaptable researcher with extensive experience spanning 14 years. His expertise managing international research programs, notably amongst key healthcare clients including Bayer Healthcare, GSK, Pfizer and Aparito, makes him a perfect fit for CMR.

Matt says, “I’m delighted to be working at CMR. Joining during the current climate has presented great challenges that no one could have anticipated, yet the company’s flexible approach and the experience of the team has enabled us to adapt our approach and deliver our clients’ research objectives to the high standards that they expect from CMR”.

CMR has also promoted Lucy Little to Qualitative Research Director. Lucy joined CMR in 2011 and has delivered countless global device research projects in a variety of therapy areas including diabetes, cardiology, gastroenterology and cancer and wound care along with surgical equipment.

CEO George Ashford is delighted with the enhanced senior team, “Matt’s knowledge and leadership experience combined with Lucy’s key expertise for delivering outstanding research has given me the freedom to broaden CMR’s research opportunities. Whilst allowing me the freedom to fulfil our key business objectives, this change in structure will also still allow me to do what I love and offer a high level of consultancy on projects where needed”.